Effectiveness of Nirmatrelvir/Ritonavir or Molnupiravir Use in Immunocompromised Patients on B-Cell-Depleting Therapy With COVID-19: A Target Trial Emulation Study.

Rituxan (rituximab) - Roche

Ocrevus (ocrelizumab) - Roche

Paxlovid (nirmatrelvir/ritonavir) - Pfizer

Lagevrio (molnupiravir) - Ridgeback Biotherap, Merck (MSD)

http://www.ncbi.nlm.nih.gov/pubmed/41132135

Abhijit Duggal; Cassandra Calabrese; Gretchen L Sacha; Leonard Calabrese; Shravan Kethireddy; Shuaiqi Huang; Xiaofeng F Wang; Yifan Wang; Yiying Fan

Oct 24, 2025